MAROSTICA, ELEONORA
 Distribuzione geografica
Continente #
NA - Nord America 528
EU - Europa 329
AS - Asia 272
AF - Africa 1
SA - Sud America 1
Totale 1.131
Nazione #
US - Stati Uniti d'America 518
CN - Cina 243
IE - Irlanda 137
UA - Ucraina 61
FI - Finlandia 43
DE - Germania 27
SG - Singapore 27
SE - Svezia 20
GB - Regno Unito 15
IT - Italia 14
CA - Canada 6
BE - Belgio 5
MX - Messico 4
PT - Portogallo 3
BR - Brasile 1
CH - Svizzera 1
FR - Francia 1
GR - Grecia 1
HK - Hong Kong 1
MU - Mauritius 1
NL - Olanda 1
TR - Turchia 1
Totale 1.131
Città #
Dublin 137
Chandler 120
Jacksonville 86
Nanjing 62
Beijing 43
Ashburn 31
Ann Arbor 29
Boardman 29
Wilmington 28
Nanchang 27
Singapore 25
Jiaxing 20
Princeton 18
Dearborn 17
Hebei 17
Lawrence 16
Shenyang 16
Tianjin 16
Medford 13
Shanghai 12
Houston 10
Helsinki 8
Milan 8
Brussels 5
Changsha 5
Hangzhou 5
Renton 5
Seattle 5
Toronto 5
Woodbridge 5
Morelia 4
Bobadela 3
Falls Church 3
Jinan 3
Kunming 3
Lanzhou 3
Los Angeles 3
Ningbo 3
Dallas 2
Norwalk 2
Pavia 2
Qingdao 2
Santa Clara 2
Washington 2
Dolo 1
Groningen 1
Haikou 1
Hefei 1
Muggiò 1
Newton 1
Piscataway 1
Redwood City 1
San Francisco 1
Surrey 1
São Paulo 1
Tappahannock 1
Vicenza 1
Xian 1
Zurich 1
Totale 875
Nome #
First-order longitudinal population model of FEV1 data: single-trial modeling and meta-analysis 94
Continuous-time Markov modelling of flexible-dose depression trials 81
Population Pharmacokinetic Model of Ibrutinib, a BTK Inhibitor for the Treatment of B-cell malignancies 73
Integration of response, tolerability and dropout in flexible-dose trials: a case study in depression 71
A state-space approach to disease and dropout modelling in Phase II clinical trials 69
Population state-space modelling of patient responses in antidepressant studies 68
Second-order indirect response modelling of complex biomarker dynamics 67
Second order Markov modelling of HAMD responses in depression trials 67
A PCA approach to population analysis: with application to a Phase II depression trial 66
PCA-based modelling in antidepressant trials: a pre-mechanistic approach 62
Disease and dropout modelling in depression trials: a state-space approach 58
Joint Modeling of Efficacy, Dropout, and Tolerability in Flexible-Dose Trials: A Case Study in Depression 58
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies 56
Population model of longitudinal FEV1 data in asthmatics: meta-analysis and predictability of placebo response 52
The GHRH+arginine stimulated pituitary GH secretion in children and adults with Prader-Willi syndrome shows age- and BMI-dependent and genotype-related differences 52
Deconvolution-based assessment of pituitary GH secretion stimulated with GHRH+arginine in Prader-Willi adults and obese controls 51
A new, second-order indirect model of depression time course 48
Population modelling of patient responses in antidepressant studies: A stochastic approach 43
Totale 1.136
Categoria #
all - tutte 4.568
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.568


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020102 0 0 0 0 0 13 0 28 19 33 8 1
2020/2021125 17 12 5 14 0 15 2 17 3 20 16 4
2021/202279 3 1 5 3 3 3 2 5 8 1 10 35
2022/2023332 25 34 5 26 26 32 0 14 157 5 7 1
2023/2024107 17 20 2 15 5 18 4 12 0 7 5 2
2024/202563 7 25 3 3 22 3 0 0 0 0 0 0
Totale 1.136